As previously reported [30], recombinant human (rh)TIMP-1 enhances CXCL12-driven migration of acute myelogenous leukemia (AML) blasts in transwell migration assay in vitro, and under the presence of CXCL12 in the lower chamber, both CXCR4 antagonist (AMD3465) and anti-TIMP-1 neutralizing antibody treatment could significantly reduce the migration of AML cells. The gene discussed is CXCR4; the disease is acute myeloid leukemia.